Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Bacterial cancer therapy in autochthonous colorectal cancer affects tumor growth and metabolic landscape
Gillian M. Mackie, … , Hiroshi Ohno, Kendle M. Maslowski
Gillian M. Mackie, … , Hiroshi Ohno, Kendle M. Maslowski
Published October 28, 2021
Citation Information: JCI Insight. 2021;6(23):e139900. https://doi.org/10.1172/jci.insight.139900.
View: Text | PDF
Research Article Gastroenterology

Bacterial cancer therapy in autochthonous colorectal cancer affects tumor growth and metabolic landscape

  • Text
  • PDF
Abstract

Bacterial cancer therapy (BCT) shows great promise for treatment of solid tumors, yet basic mechanisms of bacterial-induced tumor suppression remain undefined. Attenuated strains of Salmonella enterica serovar Typhimurium (STm) have commonly been used in mouse models of BCT in xenograft and orthotopic transplant cancer models. We aimed to better understand the tumor epithelium–targeted mechanisms of BCT by using autochthonous mouse models of intestinal cancer and tumor organoid cultures to assess the effectiveness and consequences of oral treatment with aromatase A–deficient STm (STmΔaroA). STmΔaroA delivered by oral gavage significantly reduced tumor burden and tumor load in both a colitis-associated colorectal cancer (CAC) model and in a spontaneous Apcmin/+ intestinal cancer model. STmΔaroA colonization of tumors caused alterations in transcription of mRNAs associated with tumor stemness, epithelial-mesenchymal transition, and cell cycle. Metabolomic analysis of tumors demonstrated alteration in the metabolic environment of STmΔaroA-treated tumors, suggesting that STmΔaroA imposes metabolic competition on the tumor. Use of tumor organoid cultures in vitro recapitulated effects seen on tumor stemness, mesenchymal markers, and altered metabolome. Furthermore, live STmΔaroA was required, demonstrating active mechanisms including metabolite usage. We have demonstrated that oral BCT is efficacious in autochthonous intestinal cancer models, that BCT imposes metabolic competition, and that BCT has direct effects on the tumor epithelium affecting tumor stem cells.

Authors

Gillian M. Mackie, Alastair Copland, Masumi Takahashi, Yumiko Nakanishi, Isabel Everard, Tamotsu Kato, Hirotsugu Oda, Takashi Kanaya, Hiroshi Ohno, Kendle M. Maslowski

×

Figure 5

STmΔaroA treatment alters the metabolic environment of CAC tumors.

Options: View larger image (or click on image) Download as PowerPoint

STmΔaroA treatment alters the metabolic environment of CAC tumors.
Tumo...
Tumor metabolites of CAC-induced colon tumors were assessed by GC-MS. (A and B) OPLS analysis of metabolites comparing nontreated (NT) and STmΔaroA-treated tumors after 6 weeks (A) and 24 hours (B) of treatment. The size of tumors used for analysis is shown in Supplemental Figure 7, B and C. All metabolites significantly different between STmΔaroA-treated and nontreated tumors (VIP score > 1) were submitted to pathway analysis (MetaboAnalyst). (C and D) Pathway analysis for 6 weeks of STmΔaroA treatment (C) and 24 hours treatment (D), represented as the percentage of metabolites in a pathway that were altered, against P value (–log); hypergeometric test used. (E) Metabolites detected from glycolysis (pink shading) and TCA cycle (green shading), and amino acids (orange shading), with interrelationships depicted (24 hours after treatment). The x axis shows nmol/g. One-way ANOVA was performed with Bonferroni multiple-comparison test; P values shown are the multiple-comparison statistic. Data are shown as mean ± SD. Both 6-week and 24-hour analyses were performed on 2 independent experiments, with similar changes observed in both sets.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts